STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	P3L58-59	ABSTRACT, METHODS
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	P3L72-73	ABSTRACT,
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	P4L77-95	INTRODUCTION
Objectives	3	State specific objectives, including any prespecified hypotheses	P4L96-98	INTRODUCTION
Methods				
Study design	4	Present key elements of study design early in the paper		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	'5L115-120	PATIENTS AND METHODS, patient
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	P5L134-P6L152 P6L159-161	PATIENTS AND METHODS, patient population
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	P7L203-204	PATIENTS AND METHODS, statistical
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	not available	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	not available	
Bias	9	Describe any efforts to address potential sources of bias	not available	
Study size	10	Explain how the study size was arrived at	not available	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	P7L198-199	PATIENTS AND METHODS, statistical

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	P7L196-P7L205	PATIENTS AND
		(b) Describe any methods used to examine subgroups and interactions	P7L204-205	PATIENTS AND
		(c) Explain how missing data were addressed	not available	
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	P6L159-161	PATIENTS AND METHODS, patient population
		(e) Describe any sensitivity analyses	P7L204-205	PATIENTS AND
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	P5L116-121	PATIENT AND METHODS, patient
		(b) Give reasons for non-participation at each stage	not available	
		(c) Consider use of a flow diagram	not available	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	P8L213 P21 TABLE 1	RESULTS
		(b) Indicate number of participants with missing data for each variable of interest	P5L116-121	PATIENT AND
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	P9L254	RESULTS
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	P8L221-P9L253	RESULTS
		Case-control study—Report numbers in each exposure category, or summary measures of exposure		RESULTS
		Cross-sectional study—Report numbers of outcome events or summary measures		RESULTS
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	P21 TABLE 1 P22 TABLE 2	RESULTS
		(b) Report category boundaries when continuous variables were categorized	P21 TABLE 1	RESULTS
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	P21 TABLE 1	RESULTS
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	not available	RESULTS
Discussion				
Key results	18	Summarise key results with reference to study objectives	P10L290-L300	DISCUSSION
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	P13L470-473	DISCUSSION

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	P10L281-289 P12L414-P13L469	DISCUSSION
Generalisability	21	Discuss the generalisability (external validity) of the study results	P13L475-480	CONCLUSIONS
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	P15L498	DISCUSSION

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/jtd-20-1241
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.